Story
Hims & Hers Stock Navigates Credibility Test Ahead of Key FDA Decision

Shares of Hims & Hers Health (HIMS) are at a crossroads as the telehealth company's rapid growth narrative collides with significant questions about its profitability and business model. With a crucial U.S. Food and Drug Administration (FDA) advisory committee meeting scheduled for July 23–24, investors are closely watching for a catalyst that could either validate the company's high valuation or reinforce bearish concerns.
The Growth Story
The bull case for Hims & Hers is centered on its formidable revenue expansion. The company's revenue surged from $527 million in fiscal 2022 to $2.35 billion in fiscal 2025, with consensus estimates projecting further growth to $3.44 billion by fiscal 2027, according to the source material.
The April 1, 2026, launch of its oral Wegovy offering provided an initial boost, prompting analysts at Barclays and Canaccord to raise their price targets to $39 and $40, respectively. Furthermore, card data from June suggests the company is on track to beat second-quarter revenue estimates and raise its guidance, according to an analysis by Truist.
Profitability and Retention Headwinds
Despite the top-line growth, the company's profitability has come under intense scrutiny. Fiscal 2026 earnings per share (EPS) estimates have been revised downward by a dramatic 77% over the past year. The company posted a significant Q1 2026 EPS miss of -$0.40 against an expected +$0.01, sending the stock down over 11% on the day of the report.
AdKey concerns for bears include:
- Valuation: The stock trades at a high multiple of 104x EV/EBITDA, which analysts note is a price for perfection. InvestingPro’s Fair Value model suggests a potential 19% downside to $26.53.
- Wegovy Churn: Bank of America has flagged a potential retention issue, as customers face a price hike from $39 in their first month to $149 in their second. The bank noted that a competitor, Ro, is already seeing declining new customers after a similar launch.
- Analyst Sentiment: Six analysts have recently revised EPS estimates downward, and the upcoming departure of the company's Chief Accounting Officer adds a layer of governance uncertainty.
FDA Peptide Decision Looms
The most significant near-term event is the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23–24. The committee will consider approving seven peptides for compounding, which bulls believe could open a major new revenue stream for Hims & Hers.
However, even a favorable outcome may not provide an immediate financial boost. Analysts at Truist have noted that meaningful revenue from peptides is unlikely to materialize before 2028. The meeting's result is expected to heavily influence investor sentiment, either by adding a new growth driver or by confirming that the company's path to sustained profitability remains challenging.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.